CHMP’s Revlimid Rebuff Will Have Limited Impact In EU Market
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.